SEARCH

SEARCH BY CITATION

References

  • 1
    Bruni, J. Phenytoin: toxicity. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995;34550.
  • 2
    Thomason, JM, Seymour, RA, Rawlins, MD. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. Community Dent Oral Epidemiol 1992;20:28891.
  • 3
    Angelopoulos, AP, Goaz, PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg 1972;34:898906.
  • 4
    Reynolds, EH. Chronic antiepileptic drug toxicity: a review. Epilepsia 1975;16:31952.
  • 5
    Aarli, JA. Phenytoin-induced depression of salivary IgA and gingival hyperplasia. Epilepsia 1976; 17:28391.
  • 6
    Dahllof, G, Modeer, T, Otteskog, P, Sundqvist, KG. Subpopulations of lymphocytes in connective tissue from phenytoin-induced gingival overgrowth. Scand J Dent Res 1985;93:50712.
  • 7
    Houck, JC, Cheng, RF, Water, MD. The effect of dilantin upon fibroblast proliferation. Proc Soc Exp Biol Med 1972;139:96971.
  • 8
    Rapport, RL, Shaw, CM. Phenytoin-related cerebellar degeneration without seizures. Ann Neurol 1977;2:4379.
  • 9
    Dam, M. Phenytoin: toxicity. In: Woodbury, DM, Penry, JK, Pippenger, CE, eds. Antiepileptic drugs. New York : Raven Press, 1982;24756.
  • 10
    Masur, H. Cerebellar atrophy following acute intoxication with phenytoin. Neurology 1990;40:18001.
  • 11
    Kuruvilla, T, Barucha, NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia 1997;38:5002.
  • 12
    Leppik, IE, Lapora, J, Loewenson, R. Seasonal incidence of phenytoin allergy unrelated to plasma levels. Arch Neurol 1985;42:1202.
  • 13
    Mattson, RH, Cramer, JA, Collins, JF, et al. Connective tissue changes, hypersensitivity, rash and blood laboratory test changes associated with antiepileptic drug therapy. Ann Neurol 1986;20:11920.
  • 14
    Haruda, F. Phenytoin hypersensitivity: 38 cases. Neurology 1979;87:14805.
  • 15
    Parker, WA, Shearer, CA. Phenytoin hepatotoxicity: a case report and review. Neurology 1979;29:1758.
  • 16
    Pisciotta, AV. Phenytoin: hematologic toxicity. In: Woodbury, DM, Penry, JK, Pippenger, CE, eds. Antiepileptic drugs. New York : Raven Press, 1982;25768.
  • 17
    Sillanpaa, M. Carbamazepine. In: Wyllie, E, ed. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore : Williams & Wilkins, 1996;80823.
  • 18
    Horowitz, S, Patwardhan, RM, Marcus, E. Hepatotoxic reactions associated with carbamazepine. Epilepsia 1988;29:14954.
  • 19
    Gilhus, NE, Matre, R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurol Scand 1986;743:1815.
  • 20
    Killian, JM. Tegretol in trigeminal neuralgia with special references to hematopoietic adverse effects. Headache 1969;9:5863.
  • 21
    Hart, RG, Easton, JD. Carbamazepine and hematologic monitoring. Ann Neurol 1982;11:30912.
  • 22
    Lahr, MB. Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 1985;37:6936.
  • 23
    Ringel, RA, Brick, JF. Perspective on carbamazepine-induced water intoxication: reversal by demeclocycline. Neurology 1986;36:15067.
  • 24
    Sillanpaa, M. Carbamazepine. Pharmacology and clinical uses. Acta Neurol Scand 1981;88(suppl. 64):S1202.
  • 25
    Mattson, RH, Cramer, JA, Collins, JF, and the VA Epilepsy Cooperative Study Group. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:14551.
  • 26
    Mattson, RH, Cramer, JC, Collins, JF, and the VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:76571.
  • 27
    Brodie, MJ, Richens, A, Yuen, AC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:4769.
  • 28
    Pellock, JM. Carbamazepine adverse effects in children and adults. Epilepsia 1987;28(suppl. 3):S6470.
  • 29
    Blackburn, SC, Oliart, AD, Garcia, Rodriguez LA, Perez, Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998;18:127783.
  • 30
    Ounsted, C. The hyperkinetic syndrome in epileptic children. Lancet 1955;1:30311.
  • 31
    Wolf, SM, Forsythe, A. Psychology, pharmacotherapy, and new diagnostic approaches. In: Meinardi, H, Rowan, AJ, eds. Advances in epileptology. Amsterdam : Swets & Zeitlinger, 1977:1247.
  • 32
    Cramer, JA, Mattson, RH. Phenobarbital: toxicity. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995:40920.
  • 33
    Reynolds, EH. Chronic antiepileptic toxicity: a review. Epilepsia 1974;16:31952.
  • 34
    Gabriel, RM. Delayed reaction to PRM in pregnancy. BMJ 1957;1:344.
  • 35
    Welton, DG. Exfoliative dermatitis and hepatitis due to phenobarbital. JAMA 1950;143:2324.
  • 36
    Hawkins, CF, Meynell, MJ. Macrocytosis and macrocytic anemia caused by anticonvulsant drugs. Am J Med 1958;27:4563.
  • 37
    Murphy, JV, Marquardt, KM. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 1982;39:5912.
  • 38
    Hjelm, M, Oberholzer, V, Seakins, J, Thomas, S, Kay, JDS. Valproate-induced inhibition of urea synthesis and hyperammonemia in healthy subjects. Lancet 1986;2:859.
  • 39
    Hjelm, M, Oberholzer, V, Seakins, J, Thomas, S, Kay, JDS. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. BMJ 1986;292:234.
  • 40
    de An, JC. Valproate. In: Wyllie, E, ed. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore : Williams & Wilkins, 1996;80823.
  • 41
    de Lgado, MR, Riela, AR, Mills, J, Browne, R, Roach, ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994;9:3114.
  • 42
    Kreuz, W, Linde, M, Funk, R, et al. Valproate therapy induces von Willebrand disease type I. Epilepsia 1991;33:17884.
  • 43
    Kreuz, W, Linde, M, Frunk, R, et al. Induction of von Willebrand disease type I by valproic acid. Lancet 1990;335:13501.
  • 44
    Kis, B, Szupera, Z, Mezei, Z, Geese, A, Telegdy, G, V'ecsci, L. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia 1999;40:30710.
  • 45
    Zeller, JA, Schlesinger, S, Runge, U, Kessler, C. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999;40:1869.
  • 46
    Plantin, PM, Carter, H, Le, Bihan G, Clouard, P, Lellouche, F, Leroy, JP. Syndrome d'hypersensibilite médicamenteuse au cours d'un traitement par acide valproique. Presse Med 1995;24:1624.
  • 47
    Asconape, JJ, Pency, JK, Dreifuss, RE, et al. Valproate-associated pancreatitis. Epilepsia 1992;34:11723.
  • 48
    Dreifuss, FE. Valproic acid: toxicity. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995;40920.
  • 49
    Rettie, AE, Rettenmeier, AW, Howald, WN, Baillie, TA. Cytochrome P450-catalyzed formation of VPA, a toxic metabolite of valproic acid. Science 1987;235:8903.
  • 50
    Dreifuss, FE, Santilli, N, Langer, DH, Sweeney, KP, Moline, KA, Menander, KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:37985.
  • 51
    Scheffner, D, Konig, S, Rauterberg-Ruland, I, Kochen, W, Hofman, WJ, Unkelbach, S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29:53042.
  • 52
    Dreifuss, FE, Langer, DH, Moline, KA, Maxwell, JE. Valproic acid hepatic fatalities II: US experience since 1984. Neurology 1988; 33:2017.
  • 53
    de Toledo, JC, Toledo, C, de Cerce, J, Ramsay, RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:3946.
  • 54
    Wolf, SM, Shinnar, S, Kang, H, Gil, KB, Moshe, SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:12035.
  • 55
    Harden, CL, Hosain, S, Nikolov, B, Labar, DR. Evaluation of gabapentin in an outpatient and office-based sample of epilepsy patients. J Epilepsy 1998;11:1305.
  • 56
    Sadler, M. Lamotrigine associated with insomnia. Epilepsia 1999;40:3225.
  • 57
    Ettinger, AB, Weisbrot, DM, Saracco, J, Dhoon, A, Kanner, A, de Vinsky, O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:8747.
  • 58
    Faught, E, Morris, G, Jacobson, M, et al., and the Postmarketing Antiepileptic Drug Survey (PADS) Group. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Epilepsia 1999;40:113540.
  • 59
    Mackay, FJ, Wilton, LV, Pearce, GL, Freemantle, SN, Mann, RD. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38:8816.
  • 60
    Glaxo Wellcome Company. Lamictal package insert. October 1999.
  • 61
    Messenheimer, J, Mullens, EL, Giorgi, L, Young, F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:28196.
  • 62
    Besag, FMC, Wallace, SJ, Dulac, O, Alving, J, Spencer, SC, Hosking, G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:9917.
  • 63
    Li, LM, Russo, M, O'Donoghur, MF, Duncan, JS, Sander, JWAS. Allergic skin rash with lamotrigine and concomitant valproate therapy. Arq Neuropsiquiatr 1996;54:479.
  • 64
    Schlumberger, E, Chavez, F, Palacios, L, Rey, E, Pajet, N, Dulac, O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:35967.
  • 65
    Jones, D, Chhiap, V, Resor, S, Appel, G, Grossman, ME. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Der-matol 1997;36:10168.
  • 66
    Makin, AJ, Fitt, S, Williams, R. Fulminant hepatic failure induced by lamotrigine. BMJ 1995;311:292.
  • 67
    Schlienger, RG, Shear, NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39(suppl. 7):S37.
  • 68
    Leeder, JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39(suppl. 7):S816.
  • 69
    Crawford, P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7:20711.
  • 70
    Ben-Menachem, E, Henrickson, O, Dam, M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:53943.
  • 71
    Shorvon, SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl. 2):S1822.
  • 72
    Leppik, IE, Gram, L, de Aton, R, Sommerville, KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999;33:23546.
  • 73
    Leppik, IE. Tiagabine: the safety landscape. Epilepsia 1995;36(suppl. 6):S103.
  • 74
    Shinnar, S, Berg, A, Hauser, WA, et al. Evaluations of the incidence of status epilepticus in association with tiagabine therapy [Abstract]. Epilepsia 1997;38(suppl. 3):65.
  • 75
    Eckardt, KM, Steinhoff, BJA. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment [Abstract]. Epilepsia 1998;39:6714.
  • 76
    Ettinger, AB, Bernal, OG, Andriola, MR, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:115962.
  • 77
    Schapel, G, Chadwick, D. Tiagabine and non-convulsive status epilepticus. Seizure 1996;5:1536.
  • 78
    Trinka, E, Moroder, T, Nagler, M, Staffen, W, Loscher, W, Ladurner, G. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999;8:414.
  • 79
    Holtkamp, M, Pfeiffer, M, Buchheim, K, Meierkord, H. Tiagabine and non-convulsive status epilepticus. Nervenarzt 1999;70:11046.
  • 80
    Knake, S, Hamer, HM, Schomburg, U, Oertel, WH, Rosenow, F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8:3147.
  • 81
    Richards, DA, Lemos, T, Whitton, PS, Bowery, NG. Extracellular GABA in the ventrolateral thalamus of rats exhibiting spontaneous absence epilepsy: a microdialysis study. J Neurochem 1995;65:167480.
  • 82
    Keppra: Levetiracetam Prescribing Information: March 8, 2000.
  • 83
    Tecoma, ES. Oxcarbazepine. Epilepsia 1999;40(suppl. 5):S3746.
  • 84
    Trileptal: Oxcarbazepine Prescribing Information: March, 2000.
  • 85
    Zonegran: Zonisamide Prescribing Information: March 30, 2000.
  • 86
    Leppik, IE. Zonisamide. Epilepsia 1999;40(suppl. 5):S2329.
  • 87
    Ben-Menachem, E, French, J. Vigabatrin. In: Engel, J, Jr, Pedley, TA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott-Raven Publishers, 1997;160918.
  • 88
    French, J, Pellock, J, Ferrendelli, J, et al. Results of a multicenter, placebo-controlled, parallel study of vigabatrin (VGB, Sabril) in patients with focal epilepsy whose seizures are difficult to control [Abstract]. Neurology 1993;43(suppl. 2):A307.
  • 89
    French, JA, Mosier, M, Walker, S, et al. A double-blind placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1995;46:5461.
  • 90
    Krauss, GL, Johnson, M, Miller, NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:6148.
  • 91
    Kalviainen, R, Nousaianen, I, Mantyjarvi, M, et al. Vigabatrin, a GABA-ergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:9226.
  • 92
    Rootwelt, K, Ganes, T, Johannessen, SI. Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest 1978; 38:7316.
  • 93
    Isojarvi, JI, Pakarinen, AJ, Ylipalosaari, PJ, Myllyla, VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990;47:6706.
  • 94
    Smith, PJ, Surks, MI. Multiple effects of 5,5-diphenylhydantoin on the thyroid hormone system. Endocrine Rev 1984;5:51424.
  • 95
    de Luca, F, Arrigo, T, Pandullo, E, Siracusano, MF, Benvenga, S, Trimarchi, R. Changes in thyroid function tests induced by 2-month carbamazepine treatment in L-thyroxine-substituted hypothyroid children. Eur J Pediatr 1986;145:779.
  • 96
    Seale, CG, Morrell, MJ, Marcus, R, Paulson, A, Risinger, M. Bone mineral density in AED treated women with epilepsy [Abstract]. Epilepsia 1999;40(suppl. 7):164.
  • 97
    Pluskiewicz, W, Nowakowska, J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneous and phalanges. Ultrasound Med Biol 1997;23:5538.
  • 98
    Danner, R, Partanen, VJ, Riekkinen, P. Chronic anticonvulsive therapy, peripheral nerve conduction velocity, and EMG. Epilepsia 1981;22:67587.
  • 99
    Geladini, C, Faedda, MT, Sideri, G. Anticonvulsant therapy and its possible consequences on peripheral nervous system: a neurographic study. Epilepsia 1984;25:5025.
  • 100
    Drozdowski, W. Evaluation of the status of peripheral nerves in patients on long-term treatment with anticonvulsants based on a study of H reflex and F wave. Neurol Neurochir Pol 1986;20:4216.
  • 101
    Lovelace, RE, Horwitz, SJ. Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch Neurol 1968;18:6977.
  • 102
    Schwaninger, M, Ringled, P, Winter, R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999;40:34550.
  • 103
    Ono, H, Sakamoto, A, Eguchi, T, Fujita, N, Nomura, S, Ueda, H, Sakura, N, Ueda, K. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism 1997;46:95962.